<DOC>
	<DOCNO>NCT01111344</DOCNO>
	<brief_summary>The purpose study assess efficacy Glizigen Viusid administration treatment external anogenital wart child adolescent . The duration double-blind placebo control phase 3 clinical trial 12 week . The estimated number person recruit randomize study 76 . Variables assess : time disappearance lesion , reduction number lesion change aspect lesion .</brief_summary>
	<brief_title>Glizigen-Viudid-External Anogenital Warts Children Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Warts</mesh_term>
	<mesh_term>Condylomata Acuminata</mesh_term>
	<criteria>No previous treatment anogenital wart Negative serology HB HIV . Signed informed consent . Pregnancy Treatment steroid , immunesuppressors , immunemodulators local systemic antiviral drug . Hypersensitivity Glizigen Viusid :</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Dietary supplement</keyword>
	<keyword>Anogenital wart</keyword>
	<keyword>Viusid</keyword>
	<keyword>Glizigen</keyword>
</DOC>